Validation of Strasbourg environmental exposure chamber (EEC) ALYATEC® in mite allergic subjects with asthma

Objective: Environmental Exposure Chamber (EEC) should have standardized and controlled allergenic and non-allergenic exposures to perform reproducible clinical studies. The aim was to demonstrate that mite exposure in the Alyatec ® EEC could induce early (EAR) and/or late asthmatic reactions (LAR)...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of asthma Vol. 57; no. 2; pp. 140 - 148
Main Authors: Khayath, Naji, Doyen, Virginie, Gherasim, Alina, Radu, Carmen, Choual, Ibrahim, Beck, Nicole, Jacob, Audrey, Schoettel, Florian, Vecellio, Laurent, Domis, Nathalie, de Blay, Frédéric
Format: Journal Article
Language:English
Published: England Taylor & Francis 01.02.2020
Informa Healthcare
Subjects:
asthma
early asthmatic response
environmental experimental chamber
Environmental Sciences
Human health and pathology
late asthmatic response
Life Sciences
Mite
Pulmonology and respiratory tract
Santé publique et épidémiologie
Mite
asthma
environmental experimental chamber
late asthmatic response
early asthmatic response
ISSN:0277-0903, 1532-4303, 1532-4303
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Environmental Exposure Chamber (EEC) should have standardized and controlled allergenic and non-allergenic exposures to perform reproducible clinical studies. The aim was to demonstrate that mite exposure in the Alyatec ® EEC could induce early (EAR) and/or late asthmatic reactions (LAR) in at least 60% of subjects allergic to mite. Methods: The EEC has a volume of 147-m 3 with 20 seats. The nebulized particle number, airborne Der p1, endotoxins, and volatile organic compound (VOC) concentrations were measured. Twenty-four asthmatics allergic to mite were randomly exposed to 15, 25, and 46 ng/m 3 Der p1. Specificity was assessed in not mite-sensitized asthmatics. Results: No significant endotoxin or VOC contamination was measured. The mean inter-assay CVs were 12.5% for the airborne particle number and 28.7% for airborne Der p1 concentrations. For the three Der p1 concentrations, at least 88% of the subjects developed EAR and/or LAR, and at least 46% developed a dual response. No reaction occurred with placebo or in the control group. No severe bronchial reaction occurred. Conclusions: The Alyatec ® EEC demonstrated a tight control of allergenic and non-allergenic exposures. The EEC was clinically validated, with airborne Der p1 levels close to levels found in natural settings.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0277-0903
1532-4303
1532-4303
DOI:10.1080/02770903.2018.1563902